Hebei KuiSheng Trading Co., LTD
Assessed Supplier
- Assessed
Supplier - 1st
years
Assessed Supplier
Business Type:Trading Company
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: 19061935658
Mobile:
Tel: 19061935658
Fax:
URL: http://
Province/state: Hebei
City: Shijiazhuang
Street: 518, Mansion No. 3, Guang 'an Street, Chang 'an District, Shijiazhuang, Hebei
MaxCard:
CAS NO.302-79-4
1. We have high quality products, which are supplied directly by the factory to ensure sufficient supply.
2. We have professional services, 24 hours online to solve your problems.
3. With years of sourcing experience, we strive to bring value to every customer.
4. We hope to establish long-term stable and high-quality cooperative relations with customers from all over the world to provide the most professional and high-quality service.
5. We look forward to establishing good cooperation with you and creating a better future.
| Product Name | Retinoic Acid |
| Other Names | Vitamin A Acid/Tretinion/Tretinoin |
| CAS No. | 302-79-4 |
| Molecular Formula | C20H28O2 |
| Molecular Weight | 300.44 |
| Appearance | Yellow Powder |
| Assay | 99% |
| Grade | Cosmetic&Pharmaceutical Grade |
| Brand Name | Greenway |
Product Introduction:
Tretinoin is the acid form of vitamin A and is also known as all-trans retinoic acid or ATRA. It is a drug commonly used to treat acne vulgaris and keratosis pilaris. It is available as a cream or gel It is also used to treat acute promyelocytic leukemia. It is also available as a generic.
Its success in treating acute promyelocytic leukemia was a major breakthrough in the treatment of this type of leukemia.It works in APL because the majority of cases involve a chromosomal translocation of chromosomes 15 and 17, which causes genetic fusion of the retinoic acid receptor gene to the promyelocytic leukemia gene.
This fusion PML-RAR protein is responsible for preventing immature myeloid cells from differentiating into more mature cells. This block in differentiation is thought to cause leukemia.
ATRA acts on PML-RAR to lift this block, causing the immature promyelocytes to differentiate to normal mature blood cells thus decreasing promyelocytes.